Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1848 1
1863 1
1868 5
1869 1
1884 3
1885 4
1886 2
1887 1
1888 1
1889 2
1890 2
1892 2
1893 1
1894 2
1899 1
1907 2
1915 1
1916 1
1918 1
1920 1
1924 1
1926 1
1929 2
1930 1
1931 1
1933 1
1934 1
1935 1
1942 1
1944 1
1946 6
1947 12
1948 6
1949 4
1950 9
1951 10
1952 12
1953 9
1954 10
1955 13
1956 12
1957 9
1958 1
1959 10
1960 6
1961 8
1962 6
1963 5
1964 12
1965 11
1966 8
1967 2
1968 6
1969 8
1970 15
1971 9
1972 4
1973 7
1974 8
1975 6
1976 10
1977 17
1978 12
1979 24
1980 18
1981 18
1982 13
1983 16
1984 18
1985 23
1986 28
1987 37
1988 39
1989 40
1990 40
1991 35
1992 27
1993 36
1994 33
1995 26
1996 39
1997 23
1998 29
1999 34
2000 35
2001 42
2002 27
2003 36
2004 45
2005 26
2006 34
2007 39
2008 62
2009 42
2010 46
2011 57
2012 56
2013 69
2014 74
2015 105
2016 102
2017 110
2018 105
2019 103
2020 128
2021 136
2022 133
2023 119
2024 130
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,597 results

Results by year

Filters applied: . Clear all
Page 1
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cortés J; CLEOPATRA study group. Swain SM, et al. Among authors: clark e. Lancet Oncol. 2020 Apr;21(4):519-530. doi: 10.1016/S1470-2045(19)30863-0. Epub 2020 Mar 12. Lancet Oncol. 2020. PMID: 32171426 Clinical Trial.
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.
Piccart M, Procter M, Fumagalli D, de Azambuja E, Clark E, Ewer MS, Restuccia E, Jerusalem G, Dent S, Reaby L, Bonnefoi H, Krop I, Liu TW, Pieńkowski T, Toi M, Wilcken N, Andersson M, Im YH, Tseng LM, Lueck HJ, Colleoni M, Monturus E, Sicoe M, Guillaume S, Bines J, Gelber RD, Viale G, Thomssen C; APHINITY Steering Committee and Investigators. Piccart M, et al. Among authors: clark e. J Clin Oncol. 2021 May 1;39(13):1448-1457. doi: 10.1200/JCO.20.01204. Epub 2021 Feb 4. J Clin Oncol. 2021. PMID: 33539215 Free article. Clinical Trial.
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J; CLEOPATRA Study Group. Swain SM, et al. Among authors: clark e. N Engl J Med. 2015 Feb 19;372(8):724-34. doi: 10.1056/NEJMoa1413513. N Engl J Med. 2015. PMID: 25693012 Free PMC article. Clinical Trial.
Adjunctive Azithromycin Prophylaxis for Cesarean Delivery.
Tita AT, Szychowski JM, Boggess K, Saade G, Longo S, Clark E, Esplin S, Cleary K, Wapner R, Letson K, Owens M, Abramovici A, Ambalavanan N, Cutter G, Andrews W; C/SOAP Trial Consortium. Tita AT, et al. Among authors: clark e. N Engl J Med. 2016 Sep 29;375(13):1231-41. doi: 10.1056/NEJMoa1602044. N Engl J Med. 2016. PMID: 27682034 Free PMC article. Clinical Trial.
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.
Morschhauser F, Feugier P, Flinn IW, Gasiorowski R, Greil R, Illés Á, Johnson NA, Larouche JF, Lugtenburg PJ, Patti C, Salles GA, Trněný M, de Vos S, Mir F, Samineni D, Kim SY, Jiang Y, Punnoose E, Sinha A, Clark E, Spielewoy N, Humphrey K, Bazeos A, Zelenetz AD. Morschhauser F, et al. Among authors: clark e. Blood. 2021 Feb 4;137(5):600-609. doi: 10.1182/blood.2020006578. Blood. 2021. PMID: 33538797 Free PMC article. Clinical Trial.
CD Antigens 2001.
Mason D, André P, Bensussan A, Buckley C, Civin C, Clark E, de Haas M, Goyert S, Hadam M, Hart D, Horejsí V, Meuer S, Morrissey J, Schwartz-Albiez R, Shaw S, Simmons D, Uguccioni M, van der Schoot E, Vivier E, Zola H. Mason D, et al. Among authors: clark e. Mod Pathol. 2002 Jan;15(1):71-6. doi: 10.1038/modpathol.3880492. Mod Pathol. 2002. PMID: 11796844 Review. No abstract available.
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update.
Loibl S, Jassem J, Sonnenblick A, Parlier D, Winer E, Bergh J, Gelber RD, Restuccia E, Im YH, Huang CS, Dalenc F, Calvo I, Procter M, Caballero C, Clark E, Raimbault A, McConnell R, Monturus E, de Azambuja E, Gomez HL, Bliss J, Viale G, Bines J, Piccart M; APHINITY Steering Committee and Investigators. Loibl S, et al. Among authors: clark e. J Clin Oncol. 2024 Nov;42(31):3643-3651. doi: 10.1200/JCO.23.02505. Epub 2024 Sep 11. J Clin Oncol. 2024. PMID: 39259927 Clinical Trial.
2,597 results